



# SAFETY DATA SHEET

## VIVEPOX PRIMER 100 CURE

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier

**Product name** : VIVEPOX PRIMER 100 CURE

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Not applicable.

**Product use** : Two component coating for interior and exterior use.

#### 1.3. Details of the supplier of the safety data sheet

VIVECHROM ,  
Thesi Vathi Pigadi,  
196 00 Mandra Attikis, Greece  
Tel. +30 210 5538700,  
Fax. +30 210 5550464,  
[www.vivechrom.gr](http://www.vivechrom.gr)

**e-mail address of person responsible for this SDS** : HSE.GR@akzonobel.com

#### 1.4 Emergency telephone number

**Telephone number** : Emergency phone number of the Company  
Tel. +30(210) 5538700 (24 Hours/day, every day) & 801 11 55600 (8:00 - 16:00)  
Official advisory body (Greece)  
Tel. +30 (210) 7793 777, (24 Hours/day, every day)

**Version** : 7.02

**Date of previous issue** : 7-6-2018

## VIVEPOX PRIMER 100 CURE

**SECTION 2: Hazards identification****2.1. Classification of the substance or mixture****Product definition** : Mixture**Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]**

Flam. Liq. 3, H226

Acute Tox. 4, H312

Acute Tox. 4, H332

Skin Irrit. 2, H315

Eye Irrit. 2, H319

STOT SE 3, H335

**Ingredients of unknown toxicity** : 0%**Ingredients of unknown ecotoxicity** : 0%

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

**2.2. Label elements****Hazard pictograms** :**Signal word** : Warning

**Hazard statements** : Flammable liquid and vapour.  
 Harmful in contact with skin or if inhaled.  
 Causes serious eye irritation.  
 Causes skin irritation.  
 May cause respiratory irritation.

**Precautionary statements**

**General** : Keep out of reach of children. If medical advice is needed, have product container or label at hand.

**Prevention** : Wear protective gloves. Wear protective clothing. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not get in eyes, on skin, or on clothing.

**Response** : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or doctor if you feel unwell.

**Storage** : Keep cool.

**Disposal** : Dispose of contents and container in accordance with all local, regional, national or international regulations.

**Hazardous ingredients** : Xylene  
 ethylbenzene

**Supplemental label elements** : Not applicable.

**Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles** : Not applicable.

**Special packaging requirements**

**Containers to be fitted with child-resistant fastenings** : Not applicable.

**Tactile warning of danger** : Yes, applicable.

**2.3. Other hazards**

**VIVEPOX PRIMER 100 CURE****SECTION 2: Hazards identification**

**Other hazards which do not result in classification** : None known.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures** : Mixture

Product/ingredient name	Identifiers	% (w/w)	<b>Classification</b> Regulation (EC) No. 1272/2008 [CLP]	Type
Xylene	REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7 Index: 601-022-00-9	≥10 - ≤25	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304	[1] [2]
ethylbenzene	REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4	≤5,5	Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304	[1] [2]
toluene	REACH #: 01-2119471310-51 EC: 203-625-9 CAS: 108-88-3 Index: 601-021-00-3	≤0,3	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Repr. 2, H361d (Unborn child) STOT SE 3, H336 STOT RE 2, H373 Asp. Tox. 1, H304  <b>See Section 16 for the full text of the H statements declared above.</b>	[1] [2]

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

**Type**

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

Occupational exposure limits, if available, are listed in Section 8.

**SECTION 4: First aid measures****4.1. Description of first aid measures**

- General** : In all cases of doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and seek medical advice.
- Eye contact** : Remove contact lenses, irrigate copiously with clean, fresh water, holding the eyelids apart for at least 10 minutes and seek immediate medical advice.
- Inhalation** : Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel.
- Skin contact** : Remove contaminated clothing and shoes. Wash skin thoroughly with soap and water or use recognised skin cleanser. Do NOT use solvents or thinners.
- Ingestion** : If swallowed, seek medical advice immediately and show the container or label. Keep person warm and at rest. Do NOT induce vomiting.

**VIVEPOX PRIMER 100 CURE****SECTION 4: First aid measures**

**Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

**4.2. Most important symptoms and effects, both acute and delayed**

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

**4.3. Indication of any immediate medical attention and special treatment needed**

**Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

**Specific treatments** : No specific treatment.

See toxicological information (Section 11)

**SECTION 5: Firefighting measures****5.1. Extinguishing media**

**Suitable extinguishing media** : Recommended: alcohol-resistant foam, CO<sub>2</sub>, powders, water spray.

**Unsuitable extinguishing media** : Do not use water jet.

**5.2. Special hazards arising from the substance or mixture**

**Hazards from the substance or mixture** : Fire will produce dense black smoke. Exposure to decomposition products may cause a health hazard.

**Hazardous thermal decomposition products** : Decomposition products may include the following materials: carbon monoxide, carbon dioxide, smoke, oxides of nitrogen.

**5.3. Advice for firefighters**

**Special protective actions for fire-fighters** : Cool closed containers exposed to fire with water. Do not release runoff from fire to drains or watercourses.

**Special protective equipment for fire-fighters** : Appropriate breathing apparatus may be required.

**VIVEPOX PRIMER 100 CURE****SECTION 6: Accidental release measures****6.1. Personal precautions, protective equipment and emergency procedures**

**For non-emergency personnel** : Exclude sources of ignition and ventilate the area. Avoid breathing vapour or mist. Refer to protective measures listed in sections 7 and 8.

**For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

**6.2. Environmental precautions** : Do not allow to enter drains or watercourses. If the product contaminates lakes, rivers, or sewers, inform the appropriate authorities in accordance with local regulations.

**6.3. Methods and material for containment and cleaning up** : Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Preferably clean with a detergent. Avoid using solvents.

**6.4. Reference to other sections** : See Section 1 for emergency contact information.  
See Section 8 for information on appropriate personal protective equipment.  
See Section 13 for additional waste treatment information.

**SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

**7.1 Precautions for safe handling** : Prevent the creation of flammable or explosive concentrations of vapours in air and avoid vapour concentrations higher than the occupational exposure limits. In addition, the product should only be used in areas from which all naked lights and other sources of ignition have been excluded. Electrical equipment should be protected to the appropriate standard. Mixture may charge electrostatically: always use earthing leads when transferring from one container to another. Operators should wear antistatic footwear and clothing and floors should be of the conducting type. Keep away from heat, sparks and flame. No sparking tools should be used. Avoid contact with skin and eyes. Avoid the inhalation of dust, particulates, spray or mist arising from the application of this mixture. Avoid inhalation of dust from sanding. Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Put on appropriate personal protective equipment (see Section 8). Never use pressure to empty. Container is not a pressure vessel. Always keep in containers made from the same material as the original one. Comply with the health and safety at work laws. Do not allow to enter drains or watercourses.

**Information on fire and explosion protection**

Vapours are heavier than air and may spread along floors. Vapours may form explosive mixtures with air.

When operators, whether spraying or not, have to work inside the spray booth, ventilation is unlikely to be sufficient to control particulates and solvent vapour in all cases. In such circumstances they should wear a compressed air-fed respirator during the spraying process and until such time as the particulates and solvent vapour concentration has fallen below the exposure limits.

**7.2 Conditions for safe storage, including any incompatibilities**

**VIVEPOX PRIMER 100 CURE****SECTION 7: Handling and storage**

Store in accordance with local regulations.

**Notes on joint storage**

Keep away from: oxidising agents, strong alkalis, strong acids.

**Additional information on storage conditions**

Observe label precautions. Store in a dry, cool and well-ventilated area. Keep away from heat and direct sunlight.

Keep away from sources of ignition. No smoking. Prevent unauthorised access. Containers that have been opened must be carefully resealed and kept upright to prevent leakage.

**7.3 Specific end use(s)**

**Recommendations** : Not available.

**Industrial sector specific solutions** : Not available.

**SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

**8.1 Control parameters**Occupational exposure limits

Product/ingredient name	Exposure limit values
Xylene	<b>Υπουργείο Εργασίας και Κοινωνικών Υποθέσεων (Greece, 2/2012). Absorbed through skin.</b> TWA: 100 ppm 8 hours. TWA: 435 mg/m <sup>3</sup> 8 hours. STEL: 150 ppm 15 minutes. STEL: 650 mg/m <sup>3</sup> 15 minutes.
ethylbenzene	<b>Υπουργείο Εργασίας και Κοινωνικών Υποθέσεων (Greece, 2/2012).</b> TWA: 100 ppm 8 hours. TWA: 435 mg/m <sup>3</sup> 8 hours. STEL: 125 ppm 15 minutes. STEL: 545 mg/m <sup>3</sup> 15 minutes.
toluene	<b>Υπουργείο Εργασίας και Κοινωνικών Υποθέσεων (Greece, 2/2012). Absorbed through skin.</b> TWA: 100 ppm 8 hours. TWA: 375 mg/m <sup>3</sup> 8 hours. STEL: 150 ppm 15 minutes. STEL: 560 mg/m <sup>3</sup> 15 minutes.

**Recommended monitoring procedures** : If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

No DNELs/DMELs available.

PNECs

No PNECs available

**8.2 Exposure controls**

**VIVEPOX PRIMER 100 CURE****SECTION 8: Exposure controls/personal protection**

**Appropriate engineering controls** : Provide adequate ventilation. Where reasonably practicable, this should be achieved by the use of local exhaust ventilation and good general extraction. If these are not sufficient to maintain concentrations of particulates and solvent vapours below the OEL, suitable respiratory protection must be worn.

**Individual protection measures**

**Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** : Use safety eyewear designed to protect against splash of liquids.

**Skin protection****Hand protection****Gloves**

: When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time greater than 480 minutes according to EN 374) is recommended. When only brief contact is expected, a glove with a protection class of 2 or higher (breakthrough time greater than 30 minutes according to EN 374) is recommended.

NOTICE: The selection of a specific glove for a particular application and duration of use in a workplace should also take into account all relevant workplace factors such as, but not limited to: Other chemicals which may be handled, physical requirements (cut/puncture protection, dexterity, thermal protection), potential body reactions to glove materials, as well as the instructions/specifications provided by the glove supplier.

The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.

Gloves should be replaced regularly and if there is any sign of damage to the glove material.

Always ensure that the gloves are free from defects and that they are stored and used correctly.

**Body protection** : Personnel should wear antistatic clothing made of natural fibres or of high-temperature-resistant synthetic fibres.

**Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** : If workers are exposed to concentrations above the exposure limit, they must use appropriate, certified respirators.

**Environmental exposure controls** : Do not allow to enter drains or watercourses.

**SECTION 9: Physical and chemical properties****9.1. Information on basic physical and chemical properties****Appearance**

**Physical state** : Liquid.

**Colour** : Various: See label.

**Odour** : Not available.

**Odour threshold** : Not available.

**pH** : Not available.

**Melting point/freezing point** : Not available.

**Initial boiling point and boiling range** : Not available.

**Flash point** : Closed cup: 24°C

**Evaporation rate** : Not available.



**VIVEPOX PRIMER 100 CURE****SECTION 9: Physical and chemical properties**

<b>Upper/lower flammability or explosive limits</b>	: Not available.
<b>Vapour pressure</b>	: Not available.
<b>Vapour density</b>	: Not available.
<b>Relative density</b>	: 0,938
<b>Solubility(ies)</b>	: Insoluble in the following materials: cold water.
<b>Solubility in water</b>	: Not available.
<b>Partition coefficient: n-octanol/ water</b>	: Not available.
<b>Auto-ignition temperature</b>	: Not available.
<b>Decomposition temperature</b>	: Not available.
<b>Viscosity</b>	: Kinematic (room temperature): 5 cm <sup>2</sup> /s
<b>Explosive properties</b>	: Not available.
<b>Oxidising properties</b>	: Not available.

**9.2. Other information**

No additional information.

**SECTION 10: Stability and reactivity**

<b>10.1. Reactivity</b>	: No specific test data related to reactivity available for this product or its ingredients.
<b>10.2. Chemical stability</b>	: Stable under recommended storage and handling conditions (see Section 7).
<b>10.3. Possibility of hazardous reactions</b>	: Under normal conditions of storage and use, hazardous reactions will not occur.
<b>10.4. Conditions to avoid</b>	: When exposed to high temperatures may produce hazardous decomposition products.
<b>10.5. Incompatible materials</b>	: Keep away from the following materials to prevent strong exothermic reactions: oxidising agents, strong alkalis, strong acids.
<b>10.6. Hazardous decomposition products</b>	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

**SECTION 11: Toxicological information****11.1. Information on toxicological effects**

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

**Acute toxicity**

<b>Conclusion/Summary</b>	: Not available.
---------------------------	------------------



## VIVEPOX PRIMER 100 CURE

## SECTION 11: Toxicological information

Acute toxicity estimates

Route	ATE value
Dermal	1380,7 mg/kg
Inhalation (vapours)	11,18 mg/l

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
Xylene	Eyes - Mild irritant	Rabbit	-	87 milligrams	-
	Eyes - Severe irritant	Rabbit	-	24 hours 5 milligrams	-
	Skin - Mild irritant	Rat	-	8 hours 60 microliters	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500 milligrams	-
ethylbenzene	Skin - Moderate irritant	Rabbit	-	100 Percent	-
	Eyes - Severe irritant	Rabbit	-	500 milligrams	-
	Skin - Mild irritant	Rabbit	-	24 hours 15 milligrams	-
toluene	Eyes - Mild irritant	Rabbit	-	0,5 minutes 100 milligrams	-
	Respiratory - Irritant	Rabbit	-	870 Micrograms	-
	Eyes - Severe irritant	Rabbit	-	24 hours 2 milligrams	-
	Skin - Mild irritant	Pig	-	24 hours 250 microliters	-
	Skin - Mild irritant	Rabbit	-	435 milligrams	-
	Skin - Moderate irritant	Rabbit	-	24 hours 20 milligrams	-
	Skin - Moderate irritant	Rabbit	-	500 milligrams	-

Conclusion/Summary : Not available.

Sensitisation

Conclusion/Summary : Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Xylene	Category 3	Not applicable.	Respiratory tract irritation
toluene	Category 3	Not applicable.	Narcotic effects

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
ethylbenzene	Category 2	Not determined	hearing organs
toluene	Category 2	Not determined	Not determined

**VIVEPOX PRIMER 100 CURE****SECTION 11: Toxicological information****Aspiration hazard**

Product/ingredient name	Result
Xylene ethylbenzene toluene	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

**Other information** : Not available.

**SECTION 12: Ecological information****12.1. Toxicity**

There are no data available on the mixture itself.  
Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment.

Product/ingredient name	Result	Species	Exposure
Xylene	Acute EC50 90 mg/l Fresh water	Crustaceans - Cypris subglobosa	48 hours
	Acute LC50 8,5 ppm Marine water	Crustaceans - Palaemonetes pugio - Adult	48 hours
	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours

**Conclusion/Summary** : Not available.

**12.2. Persistence and degradability**

**Conclusion/Summary** : Not available.

**12.3. Bioaccumulative potential**

Product/ingredient name	LogP <sub>ow</sub>	BCF	Potential
Xylene	3,12	8.1 to 25.9	low
ethylbenzene	3,6	-	low
toluene	2,73	8,32	low

**12.4. Mobility in soil**

**Soil/water partition coefficient (K<sub>oc</sub>)** : Not available.

**Mobility** : Not available.

**12.5. Results of PBT and vPvB assessment**

**PBT** : Not applicable.  
P: Not available. B: Not available. T: Not available.

**vPvB** : Not applicable.  
vP: Not available. vB: Not available.

**12.6. Other adverse effects** : No known significant effects or critical hazards.

**SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

**13.1 Waste treatment methods****Product**

## VIVEPOX PRIMER 100 CURE

**SECTION 13: Disposal considerations**

- Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
- Hazardous waste** : The classification of the product may meet the criteria for a hazardous waste.
- Disposal considerations** : Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.
- Packaging**
- Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
- Disposal considerations** : Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.
- Special precautions** : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

**SECTION 14: Transport information**

**Information pertaining to IATA and ADN is considered not relevant since the material is not packaged in the correct approved packaging required of these methods of transport.**

	ADR	IMDG
14.1 UN number	UN1263	UN1263
14.2 UN proper shipping name	PAINT RELATED MATERIAL	PAINT RELATED MATERIAL
14.3 Transport hazard class(es) Class	3	3
Subsidiary class	-	-
14.4 Packing group	III	III
14.5 Environmental hazards Marine pollutant	No.	No.
Marine pollutant substances		Not available.

**VIVEPOX PRIMER 100 CURE**

**Information pertaining to IATA and ADN is considered not relevant since the material is not packaged in the correct approved packaging required of these methods of transport.**

<b>14.6 Special precautions for user</b>	Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.	
<b>HI/Kemler number</b>	30	
<b>Emergency schedules (EmS)</b>		F-E, S-E
<b>14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code</b> : Not applicable.		
<b>Additional information</b>	<p><b>Special provisions</b> 640 (E)</p> <p><b>Viscous substance exemption</b> In pack sizes less than 450 litres, under the terms of 2.2.3.1.5, this product is not subject to the provisions of ADR.</p> <p><b>Tunnel code</b> (D/E)</p>	<p><b>Viscous substance exemption</b> In pack sizes up to and including 30 litres, under the terms of 2.3.2.5, this product is not subject to the packaging, labelling and marking requirements of the IMDG Code, but both full documentation and placarding of cargo transport units is still required.</p>

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### EU Regulation (EC) No. 1907/2006 (REACH)

##### Annex XIV - List of substances subject to authorisation

##### Annex XIV

None of the components are listed.

##### Substances of very high concern

None of the components are listed, or the component present is below its threshold.

**Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles** : Not applicable.

#### Other EU regulations

**VOC** : Compliant with EU law for this product subcategory: see label

**Europe inventory** : At least one component is not listed.

Product/ingredient name	Carcinogenic effects	Mutagenic effects	Developmental effects	Fertility effects
toluene	-	-	Repr. 2, H361d (Unborn child)	-

#### Ozone depleting substances (1005/2009/EU)

Not listed.

#### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

**VIVEPOX PRIMER 100 CURE****SECTION 15: Regulatory information****Seveso Directive**

This product may add to the calculation for determining whether a site is within the scope of the Seveso Directive on major accident hazards.

**International regulations****Chemical Weapon Convention List Schedules I, II & III Chemicals**

Not listed.

**Montreal Protocol (Annexes A, B, C, E)**

Not listed.

**Stockholm Convention on Persistent Organic Pollutants**

Not listed.

**Rotterdam Convention on Prior Inform Consent (PIC)**

Not listed.

**UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

**Turkey** : At least one component is not listed.

**15.2 Chemical safety assessment** : Not applicable.

**SECTION 16: Other information**

**CEPE code** : 1

Indicates information that has changed from previously issued version.

**Abbreviations and acronyms** : ATE = Acute Toxicity Estimate  
 CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]  
 DMEL = Derived Minimal Effect Level  
 DNEL = Derived No Effect Level  
 EUH statement = CLP-specific Hazard statement  
 PBT = Persistent, Bioaccumulative and Toxic  
 PNEC = Predicted No Effect Concentration  
 RRN = REACH Registration Number  
 vPvB = Very Persistent and Very Bioaccumulative

**Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]**

Classification	Justification
Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335	On basis of test data Calculation method Calculation method Calculation method Calculation method Calculation method

**Full text of abbreviated H statements**

H225 H226 H304 H312 H315 H319 H332 H335 H336 H361d (Unborn child) H373 (hearing organs)	Highly flammable liquid and vapour. Flammable liquid and vapour. May be fatal if swallowed and enters airways. Harmful in contact with skin. Causes skin irritation. Causes serious eye irritation. Harmful if inhaled. May cause respiratory irritation. May cause drowsiness or dizziness. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. (hearing organs)
---	--

## VIVEPOX PRIMER 100 CURE

## SECTION 16: Other information

H373	May cause damage to organs through prolonged or repeated exposure.
------	--

[Full text of classifications \[CLP/GHS\]](#)

Acute Tox. 4, H312	ACUTE TOXICITY (dermal) - Category 4
Acute Tox. 4, H332	ACUTE TOXICITY (inhalation) - Category 4
Asp. Tox. 1, H304	ASPIRATION HAZARD - Category 1
Eye Irrit. 2, H319	SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2
Flam. Liq. 2, H225	FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3, H226	FLAMMABLE LIQUIDS - Category 3
Repr. 2, H361d (Unborn child)	TOXIC TO REPRODUCTION (Unborn child) - Category 2
Skin Irrit. 2, H315	SKIN CORROSION/IRRITATION - Category 2
STOT RE 2, H373 (hearing organs)	SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (hearing organs) - Category 2
STOT RE 2, H373	SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2
STOT SE 3, H335	SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3
STOT SE 3, H336	SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Narcotic effects) - Category 3

**Date of printing** : 23-12-2018

**Date of issue/ Date of revision** : 23-12-2018

**Date of previous issue** : 7-6-2018

**Version** : 7.02

[Notice to reader](#)

**IMPORTANT NOTE** The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to AkzoNobel.

**Head Office**

AkzoNobel Decorative Coatings BV, Christian Neefestraat 2, 1077 WW Amsterdam, The Netherlands